Skip to main
PTHS

PTHS Stock Forecast & Price Target

PTHS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pelthos Therapeutics is experiencing a strong uptake in prescriptions of their product ZELSUVMI for the treatment of molluscum contagiosum, and with the recent addition of new territories for commercialization, the company now covers over half of MC claims. The commercial expansion and successful launch of this first-in-class at-home treatment option positions Pelthos for significant revenue growth in the future, making it an attractive investment opportunity. The company also has a strong pipeline, including a novel NaV blocker platform targeting pain management, which could provide additional revenue opportunities in the future.

Bears say

Pelthos Therapeutics is facing challenges in their commercial operations segment, with limited traction in their ZELSUVMI product and minimal sales growth. Despite having a large and underserved market in MC cases, the lack of treatment options results in low treatment penetration and creates uncertainty for the success of Pelthos' existing and expanding pipeline. Furthermore, with no expectations for 2026 guidance and continued concerns about current trends, the company's commercial outlook is uncertain and may cause further negative sentiment among investors and analysts.

PTHS has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pelthos Therapeutics Inc (PTHS) Forecast

Analysts have given PTHS a Buy based on their latest research and market trends.

According to 6 analysts, PTHS has a Buy consensus rating as of Sep 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pelthos Therapeutics Inc (PTHS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.